- Home
- Software Solutions
- Resources
- Corporate
A Study of Apo2L/TRAIL Administered in Combination With the FOLFOX Regimen and Bevacizumab in Patients With Previously Untreated, Locally Advanced, Recurrent, or Metastatic Colorectal Cancer
Sponsors:
| Phases:
| |
| Indications | Acronym: | |
| ||
Age Groups:
| Gender: Both | |
Names:
| Enrollment: 23 | |
Additional information about NCT00873756.